ITGAM and neoplasm: Deletion of macrophage PPARc in mice not only facilitates tumor progression but also weakens the antitumor effects of PPARc agonists, with a concomitantly increased infiltration of CD11b+ myeloid cells and TAMs with proinflammatory and proangiogenic phenotypes [66].